ARS Pharmaceuticals
SPRY
SPRY
100 hedge funds and large institutions have $359M invested in ARS Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 30 increasing their positions, 29 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
3% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 29
1.36% less ownership
Funds ownership: 69.62% → 68.26% (-1.4%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Holders
100
Holding in Top 10
2
Calls
$3.99M
Puts
$2.35M
Top Buyers
| 1 | +$2.75M | |
| 2 | +$2.73M | |
| 3 | +$1.71M | |
| 4 |
Franklin Resources
San Mateo,
California
|
+$1.26M |
| 5 |
Morgan Stanley
New York
|
+$721K |
Top Sellers
| 1 | -$4.15M | |
| 2 | -$3.81M | |
| 3 | -$1.37M | |
| 4 |
CC
Clearline Capital
New York
|
-$1.03M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$1.02M |